Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diasorin SpACHIX:DIAM 78 Cash-to-Debt is 0.13 as of Jun. 2026, which is 98% below its 10-year median of 7.20. GuruFocus rates CHIX:DIAM with a GF Score™ of 78/100 and a GF Value™ of €88.84 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 209 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 83.25% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Diasorin SpA's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.13.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Diasorin SpAcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Diasorin SpA's Cash-to-Debt or its related term are showing as below:
CHIX:DIAm'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13 Med: 7.2 Max: No Debt
Current: 0.13
During the past 13 years, Diasorin SpA's highest Cash to Debt Ratio was No Debt. The lowest was 0.13. And the median was 7.20.
CHIX:DIAm's Cash-to-Debt is ranked worse than 83.25% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.13
vs CHIX:DIAm: 0.13
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Diasorin SpA Cash-to-Debt Related Terms
Diasorin SpA Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Diasorin SpA's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:DIAM vs TMO, DHR, IDXX: Cash-to-Debt Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diasorin SpA (CHIX:DIAM) has a Cash-to-Debt of 0.13 as of Jun. 2026. This is 98% below median its historical median of 7.20. Over the past decade, Diasorin SpA's Cash-to-Debt has ranged from 0.13 to 10,000.00. According to the industry distribution chart, Diasorin SpA ranks #174 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 83.3%.
Is Diasorin SpA's Cash-to-Debt too high?
Diasorin SpA's current Cash-to-Debt of 0.13 is 98% below median its 10-year median of 7.20. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 10,000.00. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.13. Diasorin SpA's value of 0.13 is 88.5% below this industry median. Based on the distribution chart, Diasorin SpA ranks #174 out of 209 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Diasorin SpA has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Cash-to-Debt compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #174 out of 209 companies for Cash-to-Debt. This places Diasorin SpA in the lower half of its industry. The industry median Cash-to-Debt is 1.13. Diasorin SpA's value of 0.13 is 88.5% below this benchmark. Historically, Diasorin SpA's own Cash-to-Debt has ranged from 0.13 to 10,000.00 over the past decade. While the company's 10-year median is 7.20 vs. the industry median of 1.13, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.13, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current Cash-to-Debt of 0.13 is 88.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current Cash-to-Debt is 0.13, which is 98% below median its own 10-year median of 7.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €88.84, compared to a current price of €74.53 — trading 16.1% below its estimated fair value. The current Cash-to-Debt is 0.13, which is 98% below median its 10-year median of 7.20 and 88.5% below the Medical Diagnostics & Research industry median of 1.13. Diasorin SpA's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Cash-to-Debt is 0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €74.53 is trading 16.1% below its estimated GF Value™ of €88.84.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for CHIX:DIAM:
Cash-to-Debt: 0.13 (98% below median its 10-year median of 7.20)
GF Value™: €88.84 vs. price of €74.53 (16.1% below fair value)
Industry Position: 88.5% below the Medical Diagnostics & Research median (#174 of 209)
No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
78GF Score
Get the complete analysis for CHIX:DIAM
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIAM has been successfully added to your 
